Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
Raphael J. Landovitz(APLA Health), Craig W. Hendrix(Johns Hopkins University), Mina C. Hosseinipour, Sue Li(Fred Hutch Cancer Center), Adeola Adeyeye(National Institutes of Health), Myron S. Cohen(University of North Carolina at Chapel Hill), Joseph J. Eron, Halima Dawood(Centre for the AIDS Programme of Research in South Africa), Beatriz Grinsztejn(University of Maryland, Baltimore), Marybeth McCauley(Family Health International 360), Ravindre Panchia(Chris Hani Baragwanath Hospital), Albert Liu(San Francisco Department of Public Health), Paul Richardson(Johns Hopkins Medicine), Manya Magnus(Milken Institute), Susan H. Eshleman(Johns Hopkins University), Ryan Kofron(APLA Health), Mark A. Marzinke(Family Health International 360), Alex R. Rinehart, David Burns(Norwegian Womens Public Health Association), Leslie Cottle(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Gordon Chau(Fred Hutch Cancer Center), David M. Margolis(University of North Carolina at Chapel Hill)
Cited by 171
Related Papers
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2012|2.5k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k